DNA-based diagnostics represent the ‘gold standard’ in microbiological testing and medical genetics. This is due to the unparalleled specificity and sensitivity of DNA-based tests which is attained only by highly specific nucleic acid amplification. Fueled by recent advances in medical genetics, molecular biology, and the revolution in genome sequencing DNA-based diagnostics has attained a market size of over $2 billion annually and continues to grow at an unprecedented rate.

Despite this phenomenal market growth, most of the market for DNA-based diagnostics remains untapped, hindered by the technological barriers and costs imposed by equipment demands or complexity of operating procedure, thus restricting its use to laboratories with a highly specialized equipment base and skilled technicians. DNA-based tests are almost totally absent from field and point-of-care settings today.

The DNA amplification technology developed by TwistDX — called RPA (Recombinase Polymerase Amplification) — enables DNA-diagnostics retaining the highest possible levels of specificity and sensitivity without substantial hardware.  Compared to current DNA diagnostics, TwistDx’s technology provides superior speed and portability enabling the ultimate use and benefit of gold standard DNA diagnostics in a much broader spectrum of applications in point of care and field settings.